KR20230084186A - 덱스메데토미딘 하이드로클로라이드를 사용한 양극성 장애 및 정신병의 치료 - Google Patents

덱스메데토미딘 하이드로클로라이드를 사용한 양극성 장애 및 정신병의 치료 Download PDF

Info

Publication number
KR20230084186A
KR20230084186A KR1020237013556A KR20237013556A KR20230084186A KR 20230084186 A KR20230084186 A KR 20230084186A KR 1020237013556 A KR1020237013556 A KR 1020237013556A KR 20237013556 A KR20237013556 A KR 20237013556A KR 20230084186 A KR20230084186 A KR 20230084186A
Authority
KR
South Korea
Prior art keywords
dexmedetomidine
pharmaceutically acceptable
subject
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237013556A
Other languages
English (en)
Korean (ko)
Inventor
프랭크 유카
로버트 라이징어
비보 마이클 드
프리소 포스트마
Original Assignee
바이오엑셀 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오엑셀 테라퓨틱스 인코포레이티드 filed Critical 바이오엑셀 테라퓨틱스 인코포레이티드
Publication of KR20230084186A publication Critical patent/KR20230084186A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237013556A 2020-10-08 2021-10-08 덱스메데토미딘 하이드로클로라이드를 사용한 양극성 장애 및 정신병의 치료 Withdrawn KR20230084186A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089135P 2020-10-08 2020-10-08
US63/089,135 2020-10-08
PCT/US2021/054171 WO2022076818A1 (en) 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride

Publications (1)

Publication Number Publication Date
KR20230084186A true KR20230084186A (ko) 2023-06-12

Family

ID=81126063

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237013556A Withdrawn KR20230084186A (ko) 2020-10-08 2021-10-08 덱스메데토미딘 하이드로클로라이드를 사용한 양극성 장애 및 정신병의 치료

Country Status (11)

Country Link
US (1) US20240024289A1 (https=)
EP (1) EP4225305A4 (https=)
JP (1) JP2023545372A (https=)
KR (1) KR20230084186A (https=)
CN (1) CN116615243A (https=)
AU (1) AU2021356687A1 (https=)
CA (1) CA3195133A1 (https=)
IL (1) IL301971A (https=)
MX (1) MX2023003993A (https=)
TW (1) TW202228682A (https=)
WO (1) WO2022076818A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
CA2884926C (en) * 2012-10-15 2021-09-21 Orion Corporation A veterinary method of alleviating noise aversion
KR101881791B1 (ko) * 2013-10-07 2018-07-25 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물
IL267689B2 (en) * 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112022000992A2 (pt) * 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes

Also Published As

Publication number Publication date
CN116615243A (zh) 2023-08-18
IL301971A (en) 2023-06-01
MX2023003993A (es) 2023-05-24
JP2023545372A (ja) 2023-10-30
CA3195133A1 (en) 2022-04-14
WO2022076818A1 (en) 2022-04-14
EP4225305A1 (en) 2023-08-16
TW202228682A (zh) 2022-08-01
US20240024289A1 (en) 2024-01-25
AU2021356687A9 (en) 2024-10-03
EP4225305A4 (en) 2024-10-23
AU2021356687A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
US12109196B2 (en) Non-sedating dexmedetomidine treatment regimens
KR20230084186A (ko) 덱스메데토미딘 하이드로클로라이드를 사용한 양극성 장애 및 정신병의 치료
TW202019388A (zh) 含右美托咪啶(dexmedetomidine)之膜調配物及其製造方法
TW202317101A (zh) 治療抑鬱狀態之方法
US12138247B2 (en) Non-sedating dexmedetomidine treatment regimens
KR20130099140A (ko) 베포타스틴 조성물
JP2006508122A (ja) チザニジンの頬及び舌下デリバリーのための医薬組成物及び投与形態並びにチザニジンを舌下又は頬に投与する方法
TW202610650A (zh) 用於增強鎮靜之咪達唑侖及氯胺酮
CN117750956A (zh) 用于治疗抑郁状态的方法
EP4731214A1 (en) Dexmedetomidine treatment regimens
EP4687890A1 (en) Methods for treating depressive states
EA045213B1 (ru) Пленочный состав, содержащий дексмедетомидин, и способ его получения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230420

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241007

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20250414

WITB Written withdrawal of application